基于RB1、PTEN和TP53的预后基因表达特征在转移性激素敏感性前列腺癌患者中的开发与独立验证
这项多中心回顾性生物标志物研究纳入226例转移性激素敏感性前列腺癌患者,其中218例可评估。以nCounter检测FFPE样本中RB1、PTEN、TP53三种抑癌基因RNA表达,两个及以上低表达定义为TSGlow。TSGlow(19.2%)与更短的去势抵抗-free生存(HR 1.8,p=0.002)和总生存(HR 2,p=0.002)独立相关。在CHAARTED试验的独立验证队列中,TSGlow与更低的去势抵抗-free生存独立相关(HR 2.2,p=0.02)。
要点
- TSGlow状态(三基因中≥2个低表达)见于19.2%的转移性激素敏感性前列腺癌患者。
- TSGlow与更短的去势抵抗-free生存(HR 1.8)和总生存(HR 2)独立相关。
- CHAARTED验证队列中TSGlow与更低的去势抵抗-free生存独立相关(HR 2.2)。
核心结论
- TSGlow表达与转移性激素敏感性前列腺癌患者的不良结局相关,作者认为需在这些患者中探索新的治疗策略。
研究设计与样本
- 多中心回顾性生物标志物研究,纳入226例转移性激素敏感性前列腺癌患者,其中218例可评估;93例接受ADT,125例接受ADT+多西他赛。
- TSGlow定义为三个抑癌基因中两个或以上在FFPE样本中经nCounter检测显示低RNA表达,其余病例为TSGwt。
- 以CHAARTED试验的微阵列数据作为独立验证队列。
主要发现
- 75.7%的患者为初诊IV期,67.9%为高瘤负荷疾病。
- TSGlow(19.2%)与更短的去势抵抗-free生存独立相关(HR 1.8,p=0.002),与更短的总生存独立相关(HR 2,p=0.002)。
- 在CHAARTED试验中,TSGlow与更低的去势抵抗-free生存独立相关(HR 2.2,p=0.02)。
- TSGlow患者中未观察到不同治疗间的临床结局差异;TSGwt组中ADT+多西他赛对去势抵抗-free生存(HR 0.4,p<0.001)和总生存(HR 0.4,p=0.001)有显著获益。
- 两个系列中均未观察到TSG特征与治疗之间的交互作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究局限性包括回顾性设计。
- 研究局限性包括样本量小。
- 研究局限性包括未纳入接受ADT+抗雄激素受体治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor suppressor genes (TSGs) RB1, PTEN, and TP53 are associated with an aggressive evolution and treatment resistance in castration-resistant prostate cancer (CRPC). OBJECTIVE: To study the clinical implications of TSG mRNA expression in mHSPC patients. DESIGN, SETTING, AND PARTICIPANTS: This is a multicenter retrospective biomarker study in mHSPC patients. TSGlow status was defined when two or more out of the three TSGs presented low RNA expression by nCounter in formalin-fixed paraffin-embedded samples and TSGwt for the remaining cases. The microarray data from the CHAARTED trial were analyzed as an independent validation cohort. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Molecular data were correlated with CRPC-free survival (CRPC-FS) and overall survival (OS) by the Kaplan-Meier method and multivariate Cox analysis. RESULTS AND LIMITATIONS: A total of 226 patients were included, of whom 218 were eligible: 93 were treated with ADT and 125 with ADT + D; 75.7% presented de novo stage IV and 67.9% high-volume disease. TSGlow (19.2%) was independently correlated with shorter CRPC-FS (hazard ratio [HR] 1.8, p = 0.002) and OS (HR 2, p = 0.002). In the CHAARTED trial, TSGlow was independently correlated with lower CRPC-FS (HR 2.2, p = 0.02); no differences in clinical outcomes according to treatment were observed in TSGlow patients, while a significant benefit was observed for ADT + D in the TSGwt group for CRPC-FS (HR 0.4, p < 0.001) and OS (HR 0.4, p = 0.001). However, no interaction was observed between TSG signature and treatment in either series. Study limitations are the retrospective design, small sample size, and lack of inclusion of patients treated with ADT + ART. CONCLUSIONS: TSGlow expression correlates with adverse outcomes in patients with mHSPC. The investigation of new therapeutic strategies in these patients is warranted. PATIENT SUMMARY: The low RNA expression of tumor suppressor genes in the tumors is correlated with adverse outcomes in patients with metastatic hormone-sensitive prostate cancer.
引用
- Jiménez N, Garcia de Herreros M, Reig Ò, et al. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol Oncol. 2024. PMID: 38429210. doi:10.1016/j.euo.2023.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。